Fevzi Ozkaynak, MD

Professor of Pediatrics
Pediatric Hematology/Oncology, New York Medical College
Director, Pediatric Blood and Marrow Transplant Program
Maria Fareri Children’s Hospital at Westchester Medical Center

EDUCATION:
University of Hacettepe, School of Medicine, Ankara (1978)

POSTGRADUATE EDUCATION AND TRAINING:
Residency in Pediatrics, Hacettepe Children’s Hospital, Ankara (1978-1982)
Residency in Pediatrics, Childrens Hospital of Los Angeles (1989-1991)
Fellowship in Peds. Hem/Onc/BMT, Childrens Hospital of LA (1986-1989)

ACADEMIC APPOINTMENTS:
2009-2010: Interim Chief, Peds Hem/Onc, NYMC, Dept. of Pediatrics
2003-Present: Professor of Pediatrics, New York Medical College
1999-2003: Associate Professor of Pediatrics, New York Medical College
1994-1999: Assistant Professor of Pediatrics, New York Medical College
1992-1994: Asst. Professor of Pediatrics, University of Southern California
1994-Present: Director, Peds. Blood & Bone Marrow Transplantation, Maria Fareri Children’s Hospital at Westchester Medical Center
1990-1993: Assistant Clinical Director, Autologous Bone Marrow Transplantation Program, Division of Hematology/Oncology, Childrens Hospital of Los Angeles
1993-1994: Director, Peripheral Stem Cell Program, Childrens Hospital of Los Angeles

SELECTED ACTIVITIES:
1994-1999: Chairperson, Childrens Cancer Group Protocol #0935:
A Phase I Study of Chimeric Human/Murine AntiGD2 Monoclonal Antibody (ch14.18) with GM-CSF in Children with Neuroblastoma.

1998-Present: Vice-Chairperson, Childrens Oncology Group #ANBL0032:
Phase III Randomized Study of Chimeric Anti-GD2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue.

1997-2005: Chairperson, Childrens Oncology Group Protocol # AS973:
A Randomized Comparison Between Antibiotics Alone and Antibiotics Plus G-CSF in Pediatric Patients with Chemotherapy Induced Febrile Neutropenia.

2000-2007: Chairperson, Pediatric Blood and Marrow Consortium, A Phase I Trial of Amifostine with L-PAM, Carboplatin, Etoposide with Escalating Doses of Cyclophosphamide with Autologous PBSC in Children with Pediatric Solid Tumors

2009-Present: Chairperson, Childrens Oncology Group #ANBL0931:
A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) with GM-CSF, IL-2 AND Isotretinoin in Hgh-Risk Neuroblastoma Patients Following Myeloablative Therapy.

HOSPITAL AFFILIATIONS
Childrens Hospital LA, LA, CA, Attending, 7/1991 – 6/1994
Maria Fareri Childrens Hospital/Westchester Medical Center, Valhalla, NY, Attending, 7/1994-Present
Vassar Medical Center, Poughkeepsie, NY : Consultant, 2/1996-Present
Danbury Hospital, Danbury, CT: Consultant, 7/1997-Present
Our Lady of Mercy/Montefiore North, Bronx, NY: Consultant, 1/1999-Present